Developer docs
API playgroundTry for free, no card

Search company profiles

Ventyx Biosciences

Full company profile

uuid0000n6m

Namestring
Ventyx Biosciences
Legal namestring
Ventyx Biosciences, Inc.
Websiteurl
ventyxbio.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Ventyx Biosciences was a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California (Delaware-incorporated), focused on developing oral small-molecule therapies for patients with autoimmune and inflammatory disorders. The company's core technology is an NLRP3 inflammasome inhibitor platform targeting the innate immune system, with pipeline assets including VTX3232 (a CNS-penetrant NLRP3 inhibitor for Parkinson's disease and cardiovascular risk reduction that reduced hsCRP by nearly 80% within one week in a 175-patient Phase 2 study), VTX2735 (Phase 2 for recurrent pericarditis), VTX958/tamuzimod (IL-17-related inflammatory bowel disease program), and preclinical VEN-201 for spinal cord injury.

The business model was that of a pre-revenue clinical-stage biotech: revenue mechanics depended on future commercialization, licensing royalties, or partnership/M&A transactions rather than current product sales. The company pursued a sales-led biotech go-to-market via clinical trials and regulatory engagement, distributed clinical supply through trial sites globally (with VTX2732/2735 expansion into Canada, EU, and UK), and communicated progress via investor press releases and healthcare conferences rather than traditional commercial channels. Communication reached shareholders and the investment community through channels such as GlobeNewsWire/PR Newswire and events such as the Piper Sandler Healthcare Conference.

Customer-facing commercialization never began prior to acquisition. Ventyx raised approximately $354.6 million cumulatively across a $51M Series B (September 2021, Surveyor Capital), a $176.6M private placement (September 2022, Redmile Group), a $100M private placement (March 2024), and a $27M strategic investment from Sanofi (September 2024, with a right of first negotiation on VTX3232). The company was acquired by Eli Lilly in early 2026 for approximately $1.2 billion ($14.00 per share, all cash), completing in Q1 2026 and resulting in delisting from Nasdaq.

Short descriptiontext

Ventyx Biosciences was a clinical-stage biopharmaceutical company developing oral NLRP3 inflammasome inhibitors for autoimmune and inflammatory diseases including Parkinson's, cardiovascular risk, IBD, and recurrent pericarditis; founded 2018 in San Diego, it was acquired by Eli Lilly in 2026 for $1.2B.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
NLRP3 inhibitors, inflammatory disease therapeutics, oral small molecules, biopharmaceutical drug development, autoimmune disorder treatments
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Potential Commercialization
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biopharmaceutical company developing pipeline of oral NLRP3 inhibitors for inflammatory diseases. No commercialized products. Revenue potential dependent on successful clinical development and regulatory approval, or on partnership/acquisition transactions.

fiercebiotech.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1VTX3232
Description

CNS-penetrant NLRP3 inhibitor for neuroinflammatory and neurodegenerative conditions such as Parkinson's and Alzheimer's disease

finance.yahoo.com
+3 more records
Core offering1 text field

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule NLRP3 inflammasome inhibitors for inflammatory-mediated diseases. Its assets target cardiometabolic disorders, neuroinflammatory/neurodegenerative conditions such as Parkinson's disease, recurrent pericarditis, and inflammatory bowel disease. The company had no commercialized products and was acquired by Eli Lilly in early 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • VTX3232 reduced hsCRP (cardiovascular risk biomarker) by nearly 80% within the first week of Phase 2 study in 175 patients with obesity and cardiovascular risk factors.
+3 more records
Product overview1 text field

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics targeting the NLRP3 inflammasome for inflammatory-mediated diseases. The company's pipeline centers on NLRP3 inhibitors including VTX3232 (CNS-penetrant for neuroinflammatory and neurodegenerative conditions), VTX2735 (for recurrent pericarditis), VTX958 and tamuzimod (for inflammatory bowel disease), and VEN-201 (for spinal cord injury). The company was acquired by Eli Lilly in early 2026 for approximately $1.2 billion.

Product and service1 record
1VTX3232
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion ($14.00 per share in all-cash transaction), expected to close in H1 2026. Deal strengthens Eli Lilly's oral inflammatory drug pipeline with NLRP3 inhibitors targeting cardiometabolic, CNS, and IBD indications. Ventyx shareholders approved the merger on March 3, 2026. Transaction completed and Ventyx delisted from Nasdaq.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-23
Description

Sanofi made a $27 million strategic investment in Ventyx Biosciences, purchasing Series A non-voting preferred stock. The investment grants Sanofi an exclusive right of first negotiation for certain VTX3232 program rights - a CNS-penetrant NLRP3 inhibitor under development for neuroinflammatory conditions. Transaction closed September 23, 2024. Sanofi subsequently engaged in ongoing negotiations regarding VTX3232 rights following positive Phase 2 data in October 2025.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sanofi took a $27M strategic stake in Ventyx and held right of first negotiation for VTX3232, with substantial inflammation and rare disease franchises (Dupixent). It is a relevant broad incumbent peer and prior partnership counterparty.

TypeBroad incumbent
Description

AbbVie operates a broad immunology franchise (Skyrizi, Rinvoq) addressing inflammatory bowel disease and other autoimmune conditions where Ventyx's IL-17 and NLRP3 programs compete. It is a broad incumbent setting commercial and pricing benchmarks.

TypeDirect peer
Description

Novartis acquired Inflazome's NLRP3 inhibitor portfolio (IZD334 and related programs) targeting inflammatory diseases. It is a direct competitor to Ventyx in the NLRP3 space with substantially greater resources.

TypeBroad incumbent
Description

Pfizer's etrasimod and broader inflammation pipeline targets IBD and inflammatory diseases overlapping with Ventyx's tamuzimod/VTX958 program. It is a broad incumbent competitor in autoimmune indications.

TypeDirect peer
Description

Olatec is developing dapansutrile, an oral NLRP3 inhibitor being studied in inflammatory and cardiometabolic indications including cardiovascular disease and gout. It is the most direct NLRP3-mechanism peer to Ventyx's pipeline.

TypeBroad incumbent
Description

Eli Lilly acquired Ventyx for $1.2B in 2026 and operates a large cardiometabolic, immunology, and neurology franchise (including GLP-1s) that will develop the Ventyx NLRP3 assets. As the new parent, it defines the development path for the acquired pipeline.

TypeEmerging player
Description

Zydus has advanced NLRP3 and inflammasome-related research programs in cardiometabolic and inflammatory indications. As an emerging player with partial mechanistic overlap, it represents an additional competitive threat to Ventyx's positioning.

TypeBroad incumbent
Description

Roche operates a major immunology and neuroscience franchise (Actemra, Ocrevus) with active inflammasome and neuroinflammation research. It represents broad incumbent competition for Ventyx's CNS and inflammatory assets.

9Bristol Myers Squibb
TypeBroad incumbent
Description

BMS markets Zeposia (S1P modulator) and has a broad autoimmune/inflammation portfolio overlapping with Ventyx's IBD and inflammatory disease focus. It represents incumbent competitive pressure in the same end indications.

10Inflazome (acquired)
TypeDirect peer
Description

Inflazome was a clinical-stage NLRP3-focused biotech acquired by Novartis in 2020; its portfolio (IZD334, IZD174) represents the closest mechanistic peer to Ventyx's pipeline and validates pharma appetite for NLRP3 assets.

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors26 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ventyx Biosciences

Clinical-stage Biopharmaceuticalsventyxbio.com

Ventyx Biosciences was a clinical-stage biopharmaceutical company developing oral NLRP3 inflammasome inhibitors for autoimmune and inflammatory diseases including Parkinson's, cardiovascular risk, IBD, and recurrent pericarditis; founded 2018 in San Diego, it was acquired by Eli Lilly in 2026 for $1.2B.

What Ventyx Biosciences does

Ventyx Biosciences was a clinical-stage biopharmaceutical company founded in 2018 and headquartered in San Diego, California (Delaware-incorporated), focused on developing oral small-molecule therapies for patients with autoimmune and inflammatory disorders. The company's core technology is an NLRP3 inflammasome inhibitor platform targeting the innate immune system, with pipeline assets including VTX3232 (a CNS-penetrant NLRP3 inhibitor for Parkinson's disease and cardiovascular risk reduction that reduced hsCRP by nearly 80% within one week in a 175-patient Phase 2 study), VTX2735 (Phase 2 for recurrent pericarditis), VTX958/tamuzimod (IL-17-related inflammatory bowel disease program), and preclinical VEN-201 for spinal cord injury.

The business model was that of a pre-revenue clinical-stage biotech: revenue mechanics depended on future commercialization, licensing royalties, or partnership/M&A transactions rather than current product sales. The company pursued a sales-led biotech go-to-market via clinical trials and regulatory engagement, distributed clinical supply through trial sites globally (with VTX2732/2735 expansion into Canada, EU, and UK), and communicated progress via investor press releases and healthcare conferences rather than traditional commercial channels. Communication reached shareholders and the investment community through channels such as GlobeNewsWire/PR Newswire and events such as the Piper Sandler Healthcare Conference.

Customer-facing commercialization never began prior to acquisition. Ventyx raised approximately $354.6 million cumulatively across a $51M Series B (September 2021, Surveyor Capital), a $176.6M private placement (September 2022, Redmile Group), a $100M private placement (March 2024), and a $27M strategic investment from Sanofi (September 2024, with a right of first negotiation on VTX3232). The company was acquired by Eli Lilly in early 2026 for approximately $1.2 billion ($14.00 per share, all cash), completing in Q1 2026 and resulting in delisting from Nasdaq.

Ventyx Biosciences firmographics

Firmographics
Name
Ventyx Biosciences
Legal name
Ventyx Biosciences, Inc.
Website
https://ventyxbio.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
101–250 employees
Short description
Ventyx Biosciences was a clinical-stage biopharmaceutical company developing oral NLRP3 inflammasome inhibitors for autoimmune and inflammatory diseases including Parkinson's, cardiovascular risk, IBD, and recurrent pericarditis; founded 2018 in San Diego, it was acquired by Eli Lilly in 2026 for $1.2B.
Ownership category
akta.pro rank

Ventyx Biosciences industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAI
Gastroenterology & Hepatology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals

Keywords

  • NLRP3 inhibitors
  • Inflammatory disease therapeutics
  • Oral small molecules
  • Biopharmaceutical drug development
  • Autoimmune disorder treatments

Where Ventyx Biosciences is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ventyx Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Drug Development and Potential Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing pipeline of oral NLRP3 inhibitors for inflammatory diseases. No commercialized products. Revenue potential dependent on successful clinical development and regulatory approval, or on partnership/acquisition transactions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Ventyx Biosciences product offering

Product offering

Core offering

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule NLRP3 inflammasome inhibitors for inflammatory-mediated diseases. Its assets target cardiometabolic disorders, neuroinflammatory/neurodegenerative conditions such as Parkinson's disease, recurrent pericarditis, and inflammatory bowel disease. The company had no commercialized products and was acquired by Eli Lilly in early 2026.

Product overview

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics targeting the NLRP3 inflammasome for inflammatory-mediated diseases. The company's pipeline centers on NLRP3 inhibitors including VTX3232 (CNS-penetrant for neuroinflammatory and neurodegenerative conditions), VTX2735 (for recurrent pericarditis), VTX958 and tamuzimod (for inflammatory bowel disease), and VEN-201 (for spinal cord injury). The company was acquired by Eli Lilly in early 2026 for approximately $1.2 billion.

Differentiator

Problem solved

Functional benefit

Brands

  • VTX3232: CNS-penetrant NLRP3 inhibitor for neuroinflammatory and neurodegenerative conditions such as Parkinson's and Alzheimer's disease
  • VTX2735
  • Tamuzimod
  • VTX958

Products and services

  • VTX3232

Quantifiable outcome

  • VTX3232 reduced hsCRP (cardiovascular risk biomarker) by nearly 80% within the first week of Phase 2 study in 175 patients with obesity and cardiovascular risk factors.
  • +3 more outcomes

Companies that use Ventyx Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Ventyx Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Ventyx Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 7 January 2026Eli Lilly agreed to acquire Ventyx Biosciences for approximately $1.2 billion ($14.00 per share in all-cash transaction), expected to close in H1 2026. Deal strengthens Eli Lilly's oral inflammatory drug pipeline with NLRP3 inhibitors targeting cardiometabolic, CNS, and IBD indications. Ventyx shareholders approved the merger on March 3, 2026. Transaction completed and Ventyx delisted from Nasdaq.
  • SanoficoreStrategic or Co-development Partner · 23 September 2024Sanofi made a $27 million strategic investment in Ventyx Biosciences, purchasing Series A non-voting preferred stock. The investment grants Sanofi an exclusive right of first negotiation for certain VTX3232 program rights - a CNS-penetrant NLRP3 inhibitor under development for neuroinflammatory conditions. Transaction closed September 23, 2024. Sanofi subsequently engaged in ongoing negotiations regarding VTX3232 rights following positive Phase 2 data in October 2025.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Ventyx Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Sanofi: Sanofi took a $27M strategic stake in Ventyx and held right of first negotiation for VTX3232, with substantial inflammation and rare disease franchises (Dupixent). It is a relevant broad incumbent peer and prior partnership counterparty.
  • AbbVie: AbbVie operates a broad immunology franchise (Skyrizi, Rinvoq) addressing inflammatory bowel disease and other autoimmune conditions where Ventyx's IL-17 and NLRP3 programs compete. It is a broad incumbent setting commercial and pricing benchmarks.
  • Pfizer: Pfizer's etrasimod and broader inflammation pipeline targets IBD and inflammatory diseases overlapping with Ventyx's tamuzimod/VTX958 program. It is a broad incumbent competitor in autoimmune indications.
  • Eli Lilly: Eli Lilly acquired Ventyx for $1.2B in 2026 and operates a large cardiometabolic, immunology, and neurology franchise (including GLP-1s) that will develop the Ventyx NLRP3 assets. As the new parent, it defines the development path for the acquired pipeline.
  • Roche / Genentech: Roche operates a major immunology and neuroscience franchise (Actemra, Ocrevus) with active inflammasome and neuroinflammation research. It represents broad incumbent competition for Ventyx's CNS and inflammatory assets.
  • Bristol Myers Squibb: BMS markets Zeposia (S1P modulator) and has a broad autoimmune/inflammation portfolio overlapping with Ventyx's IBD and inflammatory disease focus. It represents incumbent competitive pressure in the same end indications.

Direct peers

  • Novartis (Inflazome/Ildong): Novartis acquired Inflazome's NLRP3 inhibitor portfolio (IZD334 and related programs) targeting inflammatory diseases. It is a direct competitor to Ventyx in the NLRP3 space with substantially greater resources.
  • Olatec Therapeutics: Olatec is developing dapansutrile, an oral NLRP3 inhibitor being studied in inflammatory and cardiometabolic indications including cardiovascular disease and gout. It is the most direct NLRP3-mechanism peer to Ventyx's pipeline.
  • Inflazome (acquired): Inflazome was a clinical-stage NLRP3-focused biotech acquired by Novartis in 2020; its portfolio (IZD334, IZD174) represents the closest mechanistic peer to Ventyx's pipeline and validates pharma appetite for NLRP3 assets.

Emerging players

  • Zydus Lifesciences: Zydus has advanced NLRP3 and inflammasome-related research programs in cardiometabolic and inflammatory indications. As an emerging player with partial mechanistic overlap, it represents an additional competitive threat to Ventyx's positioning.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Ventyx Biosciences social profiles

Digital presence

Ventyx Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ventyx Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

Ventyx Biosciences funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors26 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ventyx Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ventyx Biosciences

What does Ventyx Biosciences do?

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of oral small molecule NLRP3 inflammasome inhibitors for inflammatory-mediated diseases. Its assets target cardiometabolic disorders, neuroinflammatory/neurodegenerative conditions such as Parkinson's disease, recurrent pericarditis, and inflammatory bowel disease. The company had no commercialized products and was acquired by Eli Lilly in early 2026.

Is Ventyx Biosciences a public or private company?

Ventyx Biosciences is a private company. It is classified as corporate owned and is currently acquired.

When was Ventyx Biosciences founded?

Ventyx Biosciences was founded in 2021. It employs 101 to 250 people.

Where is Ventyx Biosciences based?

Ventyx Biosciences is headquartered in San Diego, United States, in the North America region.

How does Ventyx Biosciences make money?

One revenue line is on record: drug Development and Potential Commercialization.

Who are Ventyx Biosciences's main competitors?

Broad incumbents on record are Sanofi, AbbVie, Pfizer, Eli Lilly, Roche / Genentech and Bristol Myers Squibb. Direct peers are Novartis (Inflazome/Ildong), Olatec Therapeutics and Inflazome (acquired). Zydus Lifesciences is listed as an emerging player.

Does Ventyx Biosciences have an API?

No public API is recorded for Ventyx Biosciences.

What industry is Ventyx Biosciences in?

Ventyx Biosciences's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogAcelot Announces Appointment of Mark Forman, M.D., Ph.D., as Chief Development Officer and Chief Medical OfficerAcelot appointed Mark Forman, M.D., Ph.D., as Chief Development Officer and Chief Medical Officer. He will oversee clinical and development strategy, including the TDP-43 program for sporadic ALS. Forman previously served as CMO at Ventyx Biosciences and Passage Bio.ProactiveinvestorsParkinson's drug developers are betting big on inflammationA Jefferies research note highlights a strategic shift in Parkinson's disease drug development toward targeting neuroinflammation, noting that the addressable early-stage patient population across the US and EU is projected to exceed two million by 2035 with a potential disease-modifying therapy market approaching $8 billion. BioVie Inc. reported positive topline Phase 2 SUNRISE-PD trial data this week for its anti-inflammatory drug bezisterim, with patients showing improvements in inflammatory markers and clinical outcomes, particularly those with higher baseline inflammation. The article profiles multiple companies including Ventyx Biosciences, Tiziana Life Sciences, and Olatec Therapeutics that are developing neuroinflammation-targeting treatments as the field moves toward multi-pathway approaches.pharmaphorumLilly's GLP-1s race away in Q2, though Foundayo falls shortEli Lilly reported Q2 revenue of $23 billion, up 48% year-over-year, with Mounjaro and Zepbound growing 91% and 46% respectively. Foundayo, its oral GLP-1, brought in $98 million, below forecasts, while Novo Nordisk's Wegovy pill made nearly $500 million. Lilly also announced eight acquisitions worth over $26 billion and raised its full-year revenue guidance to $85–87 billion.BioWorldIn the mix post-Ventyx, more NLRP3s to seize?Eli Lilly acquired Ventyx Biosciences for $1.2 billion at the start of the year, highlighting NLRP3 inhibitors. A March 26 Nature paper examined mechanisms that activate the NLRP3 inflammasome, continuing research in the space.GlobeNewswireVentyx Biosciences, Inc. Investigated by the Portnoy Law FirmThe Portnoy Law Firm initiated an investigation into possible securities fraud against Ventyx Biosciences, potentially filing a class action. The firm cites a December 2025 stock drop of 15.35% to $7.94 per share, triggered by a delay in VTX2735's Phase 2 data release to Q1 2026.MorningstarEli Lilly to Buy Kelonia Therapeutics for Initial $3.25 Billion — UpdateEli Lilly agreed to buy Kelonia Therapeutics for up to $7 billion in cash, with an upfront payment of $3.25 billion and subsequent milestone payments. The deal, closing in the second half of the year, targets Kelonia's in-vivo CAR T therapy for multiple myeloma. Lilly's recent acquisitions include Centessa, Orna, and Ventyx.BioWorldIn the mix post-Ventyx, more NLRP3s to seize?Eli Lilly acquired Ventyx Biosciences for $1.2 billion at the start of the year, bringing NLRP3 inhibitors into focus. A March 26 Nature paper examined mechanisms that activate the NLRP3 inflammasome, continuing research in the space.Defense WorldJPMorgan Chase & Co. Has $2.33 Million Stock Holdings in Ventyx Biosciences, Inc. $VTYXJPMorgan Chase & Co. increased its position in Ventyx Biosciences, Inc. by 63.4% during the third quarter, acquiring an additional 290,169 shares to hold 748,088 shares worth approximately $2.33 million, representing roughly 1.05% of the company. Several other hedge funds also initiated new stakes in Ventyx Biosciences during recent quarters, with institutional investors collectively holding 97.88% of the stock. Multiple analysts simultaneously downgraded the stock from "buy" to "neutral" or "hold" ratings and lowered price targets to $14.00 on January 8th.Defense WorldVentyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of “Reduce” by AnalystsNine analysts have assigned an average recommendation of "Reduce" to Ventyx Biosciences (NASDAQ:VTYX), with four firms downgrading the stock from buy/outperform/overweight ratings to neutral/hold ratings on January 8th. HC Wainwright, Oppenheimer, Canaccord Genuity Group, and Piper Sandler all revised their ratings downward while maintaining a $14.00 price target, reflecting a notably pessimistic consensus outlook for the clinical-stage biopharmaceutical company.Investing.comVentyx Biosciences completes $1.2 billion acquisition by Eli Lilly, delists from Nasdaq By Investing.comVentyx Biosciences was acquired by Eli Lilly and delisted from Nasdaq following the completion of a $1.2 billion merger agreement. The deal involved a premium payment to Ventyx shareholders, including cash payouts and a change in company control.